{"schema_version":"secwatch.filing_event.v1","accession":"0001326190-25-000031","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2025-05-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.937473+00:00","generated_at":"2026-05-21T13:38:55.732140+00:00","sec_items":["1.01","2.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Altimmune gets $100M Hercules facility, Q1 cash $150M, MASH data expected Q2 2025","bullets":["Up to $100M term loan from Hercules; $15M funded at closing, $25M more in 2025 subject to milestones.","Interest-only for 24 months (extendable to 42); maturity June 1, 2029; no warrants.","Q1 net loss of $19.6M ($0.26 loss per share) vs $24.4M loss in Q1 2024.","Cash, equivalents & short-term investments $150M as of Mar 31, 2025; R&D expense $15.8M.","Top-line IMPACT Phase 2b MASH data expected Q2 2025; Phase 2 AUD/ALD trials expected Q2/Q3 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001326190-25-000031","json":"https://secwatch.observer/filing/0001326190-25-000031.json","markdown":"https://secwatch.observer/filing/0001326190-25-000031.md","text":"https://secwatch.observer/filing/0001326190-25-000031.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000031/0001326190-25-000031-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000031/alt-20250513x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T13:38:55.732140+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8a1ca937ec15f885c6be33ded38a1b6078a244e7","claim":"Altimmune, Inc. incurred term loan of $15.0 million with Hercules Capital, Inc. at greater of (a) the prime rate as reported in The Wall Street Journal plus 2.45% maturing June 1, 2029.","evidence_excerpt":"first Term Loan tranche was made on the Closing Date in an aggregate principal amount of $15.0 million.","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326190/000132619025000031/0001326190-25-000031-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$15.0 million"},{"label":"Counterparty","value":"Hercules Capital, Inc."},{"label":"Rate","value":"greater of (a) the prime rate as reported in The Wall Street Journal plus 2.45%"},{"label":"Maturity","value":"June 1, 2029"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}